Stock Markets May 8, 2026 11:11 AM

Analysts Cut enGene After LEGEND Data Shows Unexpected Drop in Response Rates

Updated interim results for detalimogene raise questions about commercial prospects as multiple firms lower ratings and trim targets

By Nina Shah ENGN

enGene Therapeutics has seen at least five Wall Street firms reduce their ratings after interim results from the pivotal LEGEND trial for detalimogene in BCG-unresponsive high-risk non-muscle invasive bladder cancer revealed an unexplained fall in efficacy. The anytime complete response rate slipped to 54% from 63%, with the deterioration concentrated among patients enrolled after October 2025. Analysts cited the data shift, competitive standards for response durability, and management and leadership concerns when trimming outlooks and price targets.

Analysts Cut enGene After LEGEND Data Shows Unexpected Drop in Response Rates
ENGN

Key Points

  • Updated LEGEND trial data lowered the anytime complete response rate to 54% from 63%, with the decrease concentrated among patients enrolled after October 2025.
  • At least five Wall Street firms downgraded enGene, with Raymond James cutting its price target from $27 to $4 and Piper Sandler setting a $4 target while citing data and leadership concerns.
  • Analysts and physician feedback suggest a roughly 40% 12-month CR is a minimum threshold for meaningful commercial uptake, a bar the updated profile appears to struggle to meet.

Summary

enGene Therapeutics reported updated interim data from its pivotal LEGEND study that showed a decline in measured efficacy, prompting downgrades from five Wall Street firms. The company's anytime complete response (CR) rate fell to 54% from a previously reported 63%, a change analysts say was concentrated among patients enrolled after October 2025 - a period that followed protocol amendments. The shift has raised questions about the drug's commercial viability in a competitive treatment environment.


Trial data and timing

The updated figures show the anytime CR rate decreased to 54% from 63%. Analysts point to a particular deterioration among patients enrolled after October 2025. That later-enrolled cohort followed what market participants had viewed as constructive changes to the trial protocol, but company management has not provided an explanation for the efficacy decline.


Analyst reactions

Several sell- and neutral-side analysts adjusted their recommendations and valuation assumptions after the data update. Raymond James analyst Sean McCutcheon cut his rating to Outperform from Strong Buy and reduced his price target to $4 from $27, citing that the CR rate for post-protocol patients fell from 63% to 39% and noting that management was unable to explain the dramatic drop-off in efficacy.

Guggenheimanalyst Michael Schmidt moved to Neutral and wrote that enGenenow clearly falls short of contemporary therapies, adding that physician feedback indicates a roughly 40% 12-month CR as a minimum threshold to support meaningful commercial use. Oppenheimeranalyst Leland Gershell downgraded the stock to Perform and described the company as a "show-me" story that will face constrained investor enthusiasm in the near term.

Piper Sandler analyst Allison Bratzel lowered ENGN to Neutral with a $4 price target, pointing to uncertainty in the data and leadership concerns tied to an updated employment agreement that creates an exit path for the chief medical officer after June 1.


Market valuation and cash position

Citizens analyst Silvan Turkcan noted that enGene's shares trade at a 63% discount to the company's stated $313 million in cash reserves, characterizing the stock as "fairly valued amongst biotech peers with similar development program uncertainties." The shares were trading near $1.63, down roughly $0.09 or 5.23% intraday according to available market ticks.


Implications for commercialization

Analysts said the updated efficacy profile complicates enGene's commercial case. With physician feedback pointing to a minimum bar of about a 40% 12-month CR for meaningful uptake, the deterioration in response rates for later-enrolled patients is a central concern for future adoption and competitive positioning.


Conclusion

The combination of weaker-than-expected interim efficacy, downward analyst revisions and questions around leadership and clarity from management has shifted investor sentiment. For now, the story centers on reconciling the post-October 2025 performance difference and determining whether further data or explanation can restore confidence in the program.

Risks

  • Unexplained efficacy decline among post-October 2025 enrollees creates uncertainty about ultimate trial outcomes and commercial effectiveness - impacting biotech and healthcare sector investors.
  • Leadership and governance concerns stemming from an employment agreement that provides an exit path for the chief medical officer after June 1 may heighten operational risk - relevant to investor confidence and equity valuation in the biotech sector.
  • Market valuation risk: shares trade at a large discount to stated cash reserves, reflecting peer group development uncertainties and potential implications for funding and shareholder returns.

More from Stock Markets

Nvidia CEO Jensen Huang Sees 27% Drop in Total Pay as Stock Awards Lose Value May 12, 2026 Activist Urges BWX Technologies to Revisit Shelved Reactor Plan, Sees Potential for Stock to Double May 12, 2026 S&P Moves Mexico’s Outlook to Negative, Citing Fiscal Strain and Tepid Growth May 12, 2026 Moody's Lowers Everforth Outlook to Negative Amid Elevated Leverage May 12, 2026 Moody's Moves Albemarle Outlook to Stable After Debt Cuts and Stronger Lithium Prices May 12, 2026